The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study

INTRODUCTION: The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new me...

Full description

Bibliographic Details
Main Authors: Osman Korucu, Bekir Enes Demiryürek, Gülin Morkavuk, Aysu Akbaş Korucu
Format: Article
Language:English
Published: AVES 2018-01-01
Series:Psychiatry and Clinical Psychopharmacology
Subjects:
Online Access:http://dx.doi.org/10.1080/24750573.2017.1368856
id doaj-bf69b30e80854e82822238dc25c70179
record_format Article
spelling doaj-bf69b30e80854e82822238dc25c701792021-09-02T09:46:37ZengAVESPsychiatry and Clinical Psychopharmacology2475-05732475-05812018-01-01281141810.1080/24750573.2017.13688561368856The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective studyOsman Korucu0Bekir Enes Demiryürek1Gülin Morkavuk2Aysu Akbaş Korucu3Unıversity of Health SciencesUnıversity of Health SciencesUfuk University HospitalTurkish Drug & Medical Device InstitutionINTRODUCTION: The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new medication. METHODS: Patients diagnosed with mild to moderate stage Alzheimer’s disease according to DSM-IV criteria (age: 55–85) were admitted in this multi-centred study between December 2014 and January 2017. Thirty five patients with mini mental test score between 14 and 24 were included in the study. Pittsburgh Sleep Quality Index (PSQI), Cornell Scale for Depression in Dementia (CSDD), Beck Anxiety Scale (BAS) and Standardized Mini Mental Test (SMMT) were given to all patients were used in first days of treatment and at least after 1 month. RESULTS: Twenty patients (57%) were using Donepezil and 15 patients (43%) were using Rivastigmine. Gender, marital status, educational status and family history of dementia were not statistically significant difference for both of the groups. There was no statistically significant difference between the first and second evaluation for two treatment groups in SMMT, CSDD and BAS scores (p values .748, .232 and .611, respectively). In both groups, positive effect were observed in PSQI scores after 1 month of treatment, but this positive effect was not found to be statistically significant (p: .558). DISCUSSION: When donepezil and rivastigmine were compared in this study, it was observed that they had similar positive effects on sleeping quality, but there was not statistically significant difference.http://dx.doi.org/10.1080/24750573.2017.1368856AlzheimersleepdonepezilrivastigminedementiaPittsburgh
collection DOAJ
language English
format Article
sources DOAJ
author Osman Korucu
Bekir Enes Demiryürek
Gülin Morkavuk
Aysu Akbaş Korucu
spellingShingle Osman Korucu
Bekir Enes Demiryürek
Gülin Morkavuk
Aysu Akbaş Korucu
The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
Psychiatry and Clinical Psychopharmacology
Alzheimer
sleep
donepezil
rivastigmine
dementia
Pittsburgh
author_facet Osman Korucu
Bekir Enes Demiryürek
Gülin Morkavuk
Aysu Akbaş Korucu
author_sort Osman Korucu
title The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
title_short The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
title_full The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
title_fullStr The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
title_full_unstemmed The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
title_sort effect of cholinesterase inhibitors on sleep in the patients with alzheimer’s disease: an observational prospective study
publisher AVES
series Psychiatry and Clinical Psychopharmacology
issn 2475-0573
2475-0581
publishDate 2018-01-01
description INTRODUCTION: The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new medication. METHODS: Patients diagnosed with mild to moderate stage Alzheimer’s disease according to DSM-IV criteria (age: 55–85) were admitted in this multi-centred study between December 2014 and January 2017. Thirty five patients with mini mental test score between 14 and 24 were included in the study. Pittsburgh Sleep Quality Index (PSQI), Cornell Scale for Depression in Dementia (CSDD), Beck Anxiety Scale (BAS) and Standardized Mini Mental Test (SMMT) were given to all patients were used in first days of treatment and at least after 1 month. RESULTS: Twenty patients (57%) were using Donepezil and 15 patients (43%) were using Rivastigmine. Gender, marital status, educational status and family history of dementia were not statistically significant difference for both of the groups. There was no statistically significant difference between the first and second evaluation for two treatment groups in SMMT, CSDD and BAS scores (p values .748, .232 and .611, respectively). In both groups, positive effect were observed in PSQI scores after 1 month of treatment, but this positive effect was not found to be statistically significant (p: .558). DISCUSSION: When donepezil and rivastigmine were compared in this study, it was observed that they had similar positive effects on sleeping quality, but there was not statistically significant difference.
topic Alzheimer
sleep
donepezil
rivastigmine
dementia
Pittsburgh
url http://dx.doi.org/10.1080/24750573.2017.1368856
work_keys_str_mv AT osmankorucu theeffectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT bekirenesdemiryurek theeffectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT gulinmorkavuk theeffectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT aysuakbaskorucu theeffectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT osmankorucu effectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT bekirenesdemiryurek effectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT gulinmorkavuk effectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
AT aysuakbaskorucu effectofcholinesteraseinhibitorsonsleepinthepatientswithalzheimersdiseaseanobservationalprospectivestudy
_version_ 1721176928717635584